Song Z, Zhou Q, Zhang JL, Ouyang J, Zhang ZY. Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World J Clin Cases 2024; 12(1): 32-41 [PMID: 38292624 DOI: 10.12998/wjcc.v12.i1.32]
Corresponding Author of This Article
Zhi-Yu Zhang, PhD, Doctor, Surgeon, Department of Urology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Gusu District, Suzhou 215000, Jiangsu Province, China. abner_666@126.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 6, 2024; 12(1): 32-41 Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.32
Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts
Zhen Song, Qi Zhou, Jiang-Lei Zhang, Jun Ouyang, Zhi-Yu Zhang
Zhen Song, Department of Urology, Taixing People’s Hospital, Taizhou 225400, Jiangsu Province, China
Zhen Song, Jiang-Lei Zhang, Jun Ouyang, Zhi-Yu Zhang, Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China
Qi Zhou, Department of Reproductive Medicine Center, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China
Co-first authors: Zhen Song and Qi Zhou.
Author contributions: Zhang ZY designed the research; Song Z, Zhou Q, and Zhang ZY collected and analyzed the data; Song Z and Zhou Q wrote the paper; Zhang JL and Ouyang J provided funding support for this work; Zhang ZY reviewed and revised the paper.
Supported bySuzhou Science and Technology Project, No. SYS2019053.
Institutional review board statement: The study was conducted in accordance with the Declaration of Helsinki (revised in 2013). The study was approved by the ethics committee of the First Affiliated Hospital of Soochow University (No. 119).
Informed consent statement: Informed written consent was obtained from the patient for publication of this study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All original raw data of this study can be accessed from https://figshare.com/s/f8b74c6d55ab2f144fdb. Publicly available data were also obtained from the UCSC Xena (https://xena.ucsc.edu/) TCGA database [GDC TCGA Prostate Cancer (PRAD)].
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Yu Zhang, PhD, Doctor, Surgeon, Department of Urology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Gusu District, Suzhou 215000, Jiangsu Province, China. abner_666@126.com
Received: August 21, 2023 Peer-review started: August 21, 2023 First decision: November 28, 2023 Revised: November 30, 2023 Accepted: December 15, 2023 Article in press: December 15, 2023 Published online: January 6, 2024 Processing time: 134 Days and 2.8 Hours
Core Tip
Core Tip: Marker Ki-67 (MKI67) has been established to correlate with the proliferation and metastasis of various malignant tumor cells, including those implicated in prostate cancer (PCa). Our objective is to validate the connection between MKI67 and the diagnosis as well as prognosis of PCa, by deploying two distinct patient cohorts from bioinformatics and clinical data. Within the bioinformatics data cohort, comprising 496 PCa tissue samples juxtaposed with 152 normal controls, we ascertained that MKI67 possesses a strong diagnostic ability for PCa along with a moderate prognostic prediction potential. Similarly, through our retrospective analysis of clinical data from 271 PCa patients, we confirmed the potent diagnostic capacity of MKI67 for PCa and its capability to predict prognosis to a certain extent.
